

CITATION REPORT

List of articles citing

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history

DOI: 10.1093/jnci/89.3.227

Journal of the National Cancer Institute, 1997, 89, 227-38.

Source: <https://exaly.com/paper-pdf/27912982/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
327	Teaching Elementary Bayesian Statistics with Real Applications in Science. 1997 , 51, 241-246		18
326	Response. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1634-1634	9.7	
325	Genetic counseling for BRCA1/BRCA2 testing. 1997 , 1, 91-8		24
324	Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. 1997 , 1, 75-83		9
323	BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. 1997 , 336, 1409-15		587
322	Re: probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1632-4	9.7	2
321	Teaching Elementary Bayesian Statistics with Real Applications in Science. 1997 , 51, 241		30
320	Basic population and cancer genetics and their use in the assessment of cancer risk. 1997 , 33, 2160-6		5
319	Family history of cancer and risk of breast cancer. 1997 , 72, 735-8		36
318	Breast carcinoma in carriers of BRCA1 or BRCA2 mutations: implications of proposed distinct histologic phenotypes. 1998 , 83, 2251-4		7
317	Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis of affected relatives. 1998 , 102, 348-56		17
316	Cancer genetic clinics: why do women who already have cancer attend?. 1998 , 34, 1549-53		36
315	Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. 1998 , 62, 145-58		581
314	Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. 1998 , 18, 365-75		26
313	Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1824-9	9.7	91
312	The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1039-71	9.7	268
311	BRCA1 testing--advances and retreats. 1998 , 279, 955-7		22

310	BRCA1 and BRCA2: from molecular genetics to clinical medicine. 1998 , 16, 1969-77	136
309	Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. 1998 , 9, 939-50	96
308	Functional genomics: clinical effect and the evolving role of the surgeon. 1999 , 134, 1209-15	21
307	Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. 1999 , 17, 1040-6	114
306	Risk communication in genetic testing for cancer susceptibility. 1999 , 59-66	117
305	Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1829-46	9-7 573
304	Psychological issues in genetic testing for breast cancer. 1999 , 28, 73-91	9
303	Ethnic differences in cancer risk resulting from genetic variation. 1999 , 86, 2575-2582	92
302	Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. 1999 , 340, 77-84	1134
301	Early cancer detection by microsatellite marker analysis. 1999 , 53, 114-7	1
300	The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. 1999 , 64, 963-70	181
299	Response to the Letters from Hopper and Jenkins and Foulkes et al.. 1999 , 65, 1775	5
298	Unusual recurrence of ovarian carcinoma 9 years after initial diagnosis. 1999 , 74, 495-8	5
297	Assessing risk of breast cancer. 1999 , 105, 49-58	5
296	Testing for hereditary breast and ovarian cancer in the southeastern United States. 2000 , 231, 624-34	13
295	The influence of young age and positive family history of breast cancer on the prognosis of ductal carcinoma in situ treated by excision with or without radiation therapy or by mastectomy. 2000 , 48, 943-9	30
294	Management of familial breast cancer risk. 2000 , 62, 19-33	10
293	Cancer control research 2001. 2000 , 11, 257-70	7

292	Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2. 2000 , 9, 219-35	39
291	Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status. 2000 , 79, 74-8	15
290	Breast cancer prevention trials. 2000 , 2, 558-65	12
289	In-frame deletions of BRCA1 may define critical functional domains. 2000 , 107, 385-90	28
288	Genetics and the Multidisciplinary Breast Center. 2000 , 9, 367-396	1
287	Genetic Susceptibility and Survival: Application to Breast Cancer. 2000 , 95, 28-42	15
286	Communicating genetic risk: pros, cons, and counsel. 2000 , 5, 152-61	3
285	Hereditary cancer [the evidence for current recommended management. 2000 , 1, 9-16	14
284	Prophylactic mastectomy; evolving perspectives. 2000 , 36, 567-78	7
283	Founder populations and their uses for breast cancer genetics. 2000 , 2, 77-81	41
282	Risk models in genetic epidemiology. 2000 , 9, 589-601	6
281	The predictive value of BRCA1 and BRCA2 mutation testing. 2000 , 4, 45-8	8
280	A computer model to simulate family history of breast/ovarian cancer in BRCA1 mutation carriers. 2001 , 171, 99-111	3
279	Common hereditary cancers and implications for primary care. 2001 , 358, 56-63	62
278	The effectiveness of the Gail model in estimating risk for development of breast cancer in women under 40 years of age. 2001 , 7, 34-9	31
277	Understanding mathematical models for breast cancer risk assessment and counseling. 2001 , 7, 224-32	93
276	Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. 2001 , 91, 83-8	70
275	Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families. 2001 , 17, 74	6

274	Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. 2001 , 83, 383-7		8
273	Risk models used to counsel women for breast and ovarian cancer: a guide for clinicians. 2001 , 1, 197-206		27
272	Commentary on Eccles et al.: familial breast cancer: an investigation into the outcome of treatment for early stage disease. 2001 , 1, 73-4		
271	Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. 2001 , 51, 679-90		106
270	Second primary cancers following breast cancer in the Japanese female population. 2001 , 92, 1-8		67
269	Validating and improving models for projecting the absolute risk of breast cancer. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 334-5	9.7	95
268	Risk in Numbers? Difficulties in the Transformation of Genetic Knowledge from Research to People? The Case of Hereditary Cancer. 2001 , 40, 445-453		14
267	Commentary: practical advantages of Bayesian analysis of epidemiologic data. 2001 , 153, 1222-6		175
266	A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. 2001 , 84, 704-8		74
265	Role of population-based studies in assessing genetic cancer risk. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1188-9	9.7	5
264	Pre-counseling education materials for BRCA testing: does tailoring make a difference?. 2002 , 6, 93-105		55
263	Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. 2002 , 39, 611-4		76
262	Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 858-60	9.7	34
261	Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 844-51	9.7	124
260	Population-based screening for hereditary breast cancer in a region of North-Central Italy. 2002 , 10, 299		
259	Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1564-9	9.7	58
258	Chemoprevention of breast cancer: implications for postmenopausal women. 2002 , 19, 43-78		6
257	BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. 2002 , 20, 2701-12		417

256	Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation. 2002 , 55, 665-75	23
255	Population screening for cancer-related germline gene mutations. 2002 , 3, 341-8	14
254	Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. 2002 , 94, 305-13	25
253	Limitations of the Gail model in the specialized breast cancer risk assessment clinic. 2002 , 8, 23-7	53
252	Statistical inference for familial disease clusters. 2002 , 58, 481-91	12
251	Breast cancer risk communication: challenges and future research directions: workshop report (United States). 2003 , 14, 235-9	5
250	Subjective and Objective Risks of Carrying a BRCA1/2 Mutation in Individuals of Ashkenazi Jewish Descent. 2003 , 12, 351-71	12
249	Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. 2003 , 78, 7-15	44
248	American Cancer Society guidelines for breast cancer screening: update 2003. 2003 , 53, 141-69	508
247	Genetics and the management of women at high risk for breast cancer. 2003 , 8, 466-73	26
246	Cancer genetics service provision: a comparison of seven European centres. 2003 , 6, 192-205	12
245	Application of breast cancer risk prediction models in clinical practice. 2003 , 21, 593-601	150
244	A training course for oncology nurses in familial cancer risk assessment: evaluation of knowledge and practice. 2003 , 18, 20-5	10
243	. 2003 , 237, 474-482	16
242	Rating the risk factors for breast cancer. 2003 , 237, 474-82	155
241	Genetics. 2003 , 7, 690-2	
240	Understanding hereditary breast and ovarian cancer. 2003 , 7, 591-4	
239	Nurses who provide genetics counseling need ongoing education and certification. 2003 , 30, 361-2; author reply 362	

238	BayesMendel: an R environment for Mendelian risk prediction. 2004 , 3, Article21	56
237	Hereditäres Mamma- und Ovarialkarzinom - ein Update Teil I - molekulare Grundlagen, Tumorrisikoberatung und Risikoberechnung. 2004 , 64, 900-911	5
236	Implications of the age range in a population-based BRCA1 testing program with eligibility based on family history of breast and ovarian cancer. 2004 , 8, 229-34	
235	Subjective and objective risk of breast cancer in Ashkenazi Jewish individuals at risk for BRCA1/2 mutations. 2004 , 8, 139-47	12
234	An overview of the status of imaging screening technology for breast cancer. 2004 , 15 Suppl 1, I18-I26	45
233	Hereditary cancer: guidelines in clinical practice--general overview. 2004 , 15 Suppl 4, iv121-5	6
232	Accuracy of cancer family histories: comparison of two breast cancer syndromes. 2004 , 8, 222-8	42
231	Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. 2004 , 41, 81-91	122
230	Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study. 2004 , 8, 240-7	39
229	Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. 2004 , 292, 442-52	229
228	Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. 2004 , 41, 278-85	50
227	Risk modeling in breast cancer. 2004 , 10 Suppl 1, S10-2	11
226	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. 2004 , 12, 899-906	46
225	Associations between perceived cancer risk and established risk factors in a national community sample. 2004 , 28, 1-7	54
224	Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. 2004 , 13, 83-114	195
223	Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. 2004 , 100, 479-89	70
222	Cancer genetics in primary care. 2004 , 31, 649-83, xi	6
221	Common hereditary cancer syndromes. 2004 , 20, 164-77	4

220	Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations. 2004 , 11, 236-44	29
219	Beyond medical risk: investigating the psychological factors underlying women's perceptions of susceptibility to breast cancer, heart disease, and osteoporosis. 2004 , 23, 247-58	88
218	Use of an educational computer program before genetic counseling for breast cancer susceptibility: effects on duration and content of counseling sessions. 2005 , 7, 221-9	82
217	Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. 2005 , 143, 362-79	260
216	Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. 2005 , 20, 360-5	23
215	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. 2005 , 8, 221-33	17
214	Recent developments in critical genes in the molecular biology of breast cancer. 2005 , 28, 71-5	8
213	Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods. <i>Genetic Epidemiology</i> , 2005 , 29, 141-54	2.6 2
212	Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. 2005 , 103, 1898-905	307
211	Linkage of a pedigree drawing program and database to a program for determining BRCA mutation carrier probability. 2005 , 4, 313-6	5
210	Exploratory study of ovarian intraepithelial neoplasia. 2005 , 14, 299-305	9
209	Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. 2005 , 294, 1925-33	189
208	Classification of Missense Mutations of Disease Genes. 2005 , 100, 51-60	10
207	Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. 2005 , 14, 1082-9	20
206	Innovative Bayesian Methods for Biostatistics and Epidemiology. 2005 , 25, 763-792	1
205	Identification of risk factors for prevention and early diagnosis of a-symptomatic post-menopausal women. 2005 , 52 Suppl 1, S7-22	14
204	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. 2006 , 8, R3	64
203	Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. 2006 , 70, 320-9	24

202	The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. 2006 , 192, 58-62	22
201	Digital Dermal Patterns in Carcinoma of Breast. 2006 , 8, 251-254	3
200	The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer. 2006 , 8, 653-7	4
199	Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. 2006 , 69, 171-8	24
198	A genetic model for determining MSH2 and MLH1 carrier probabilities based on family history and tumor microsatellite instability. 2006 , 69, 254-62	18
197	Effect of misreported family history on Mendelian mutation prediction models. 2006 , 62, 478-87	13
196	RNA-based analysis of BRCA1 and BRCA2 gene alterations. 2006 , 170, 93-101	40
195	Prediction of germline mutations and cancer risk in the Lynch syndrome. 2006 , 296, 1479-87	271
194	Risk prediction models for familial breast cancer. 2006 , 2, 257-74	72
193	Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. 2006 , 24, 707-15	100
192	Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. 2007 , 44, 107-21	58
191	Atypia and DNA methylation in nipple duct lavage in relation to predicted breast cancer risk. 2007 , 16, 1812-21	29
190	In Reply. 2007 , 25, 2634-2635	
189	BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. 2007 , 25, 4635-41	58
188	Einführung in die Genetische Epidemiologie. 2007 ,	
187	BRCA1, a potential predictive biomarker in the treatment of breast cancer. 2007 , 12, 142-50	125
186	Hereditary Breast Cancer. 2007 ,	
185	PancPRO: risk assessment for individuals with a family history of pancreatic cancer. 2007 , 25, 1417-22	150

184	Validity of models for predicting BRCA1 and BRCA2 mutations. 2007 , 147, 441-50	87
183	Assessing breast cancer risk and BRCA1/2 carrier probability. 2006 , 27, 5-20	17
182	Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. 2007 , 16, 216-24	25
181	Cancer genetics. 2007 , 23, 2-9	4
180	Risk and risk assessment for breast cancer: molecular and clinical aspects. 2007 , 57, 56-60	14
179	Management of the BRCA mutation carrier or high-risk patient. 2007 , 34, 15-27; abstract v	6
178	The Genetics of Breast and Gynecologic Cancers. 2007 , 43-71	
177	Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. 2007 , 28, 477-85	40
176	Incorporating medical interventions into carrier probability estimation for genetic counseling. 2007 , 8, 13	15
175	American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. 2007 , 57, 75-89	1803
174	Cancer family history reporting: impact of method and psychosocial factors. 2007 , 16, 373-82	21
173	Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. 2007 , 16, 241-60	155
172	Subjective and objective risk of ovarian cancer in Ashkenazi Jewish women testing for BRCA1/2 mutations. 2008 , 70, 135-42	13
171	Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. 2008 , 14, 18-36	9
170	Selecting a BRCA risk assessment model for use in a familial cancer clinic. 2008 , 9, 116	36
169	Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO. 2008 , 27, 4532-48	14
168	Psychological distress and quality of life associated with genetic testing for breast cancer risk. 2008 , 17, 767-73	60
167	DNA methylation in benign breast epithelium in relation to age and breast cancer risk. 2008 , 17, 1051-9	67

166	MRI screening in a clinic population with a family history of breast cancer. 2008 , 15, 452-61	21
165	A family history of breast cancer will not predict female early onset breast cancer in a population-based setting. 2008 , 8, 203	7
164	Issues in Bilateral Prophylactic Mastectomy. 2008 , 9, 6-10	
163	Genetic testing for cancer susceptibility. 2008 , 88, 705-21, v	7
162	Performance of BRCA1/2 mutation prediction models in Asian Americans. 2008 , 26, 4752-8	52
161	BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer. 2008 , 11, 193-200	2
160	Multiple Model Evaluation Absent the Gold Standard Through Model Combination. 2008 , 103, 897-909	3
159	RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. 2008 , 68, 22-5	40
158	Hereditary Gynecologic Cancer. 2008 ,	2
157	[Prophylactic mastectomy in women at high risk for breast cancer: indications and options]. 2008 , 40, 239-47	4
156	Oral contraceptive use and BRCA penetrance: a case-only study. 2009 , 18, 2107-13	16
155	Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. 2009 , 27, 2245-52	16
154	Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. 2009 , 18, 1084-91	53
153	Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients. 2009 , 113, 467-77	9
152	Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. 2009 , 15 Suppl 1, S46-55	16
151	High Risk Indicators: Microscopic Lesions, Personal and Family History, Assessment, and Management. 2009 , 1495-1508	
150	Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers. 2009 , 28, 157	25
149	Screening and prevention of breast cancer in primary care. 2009 , 36, 533-58	19

148	Breast cancer in the personal genomics era. 2010 , 11, 146-61		56
147	Outcomes of multimodality breast screening for women at increased risk of familial breast cancer. 2010 , 34, 979-86		10
146	Exploring perceptions of genetic testing: an examination of perceived accuracy over time. 2010 , 78, 34-9		5
145	A PALB2 germline mutation associated with hereditary breast cancer in Italy. 2010 , 9, 181-5		37
144	Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma. 2010 , 9, 431-8		30
143	The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. 2010 , 9, 545-53		18
142	Cancer of the Breast. 2010 , 1215-1323		
141	Comparing breast cancer risk assessment models. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 665-8	9-7	78
140	Biomedical Informatics for Cancer Research. 2010 ,		8
139	Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. 2010 , 70, 552-9		31
138	Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. 2010 , 85, 1111-20		110
137	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. 2010 , 22, 72-8		129
136	[Predictive models for identification of germline mutation carriers in Lynch syndrome]. 2010 , 134, 412-7		1
135	Cancer and Genetic Counseling. 2011 , 23-33		1
134	Inherited Cancer Syndromes. 2011 ,		1
133	Personalized management for breast cancer. 2011 , 42-57		
132	Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. 2011 , 61, 327-59		128
131	Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. 2011 , 10, 521-8		25

130	Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. 2011 , 273, 207-15	5
129	[A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition]. 2011 , 98, 779-95	5
128	Risk factor modification and projections of absolute breast cancer risk. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1037-48	9.7 64
127	Genes and Cancer. 2012 , 561-596.e6	
126	Breast Diseases. 2012 , 369-403.e3	1
125	Celebrating 70: An Interview with Don Berry. 2012 , 27,	4
124	Breast cancer risk assessment in 64,659 women at a single high-volume mammography clinic. 2012 , 19, 95-9	24
123	Selecting families eligible for pancreatic cancer screening: another brick in the wall for the early detection of pancreatic ductal adenocarcinoma and its precursors. 2012 , 44, 539-40	1
122	Genetic Counseling and Genetic Testing in the Preoperative Evaluation of Breast Cancer Patients. 2012 , 4, 102-109	1
121	Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. 2012 , 36, 702-13	17
120	Genetic susceptibility to pancreatic cancer. 2012 , 51, 14-24	150
119	The deletion of exons 3-5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families. 2013 , 12, 119-23	8
118	Enabling the use of hereditary information from pedigree tools in medical knowledge-based systems. 2013 , 46, 710-20	2
117	Breast cancer risk assessment, prevention, and the future. 2013 , 40, 525-49	7
116	Self administered screening for hereditary cancers in conjunction with mammography and ultrasound. 2013 , 12, 651-6	7
115	Frailty Models for Familial Risk with Application to Breast Cancer. 2013 , 108, 1205-1215	13
114	Roadmap to determine the point mutations involved in cardiomyopathy disorder: a Bayesian approach. 2013 , 519, 34-40	13
113	Genetic predisposition syndromes and their management. 2013 , 93, 341-62	18

112	NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. 2013 , 22, 155-63	107
111	Hereditary cancer risk assessment: essential tools for a better approach. 2013 , 11, 16	5
110	Which risk model to use? Clinical implications of the ACS MRI screening guidelines. 2013 , 22, 146-9	46
109	Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer. 2013 , 16, 357-65	62
108	The Normal Breast and Risk Factors for Breast Cancer. 2014 , 899-919	2
107	Development and validation of risk models and molecular diagnostics to permit personalized management of cancer. 2014 , 120, 11-9	9
106	Omics Approaches in Breast Cancer. 2014 ,	8
105	Breast Cancer Genomics. 2014 , 53-103	
104	Genetic testing today. 2014 , 21, 3209-15	14
103	Clinical Decision Support for Personalized Medicine. 2014 , 383-413	0
102	Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history. 2014 , 13, 423-30	2
101	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. 2014 , 160, 255-66	171
100	Twenty-five years of breast cancer risk models and their applications. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7 33
99	Genetic risk assessment for breast and gynecological malignancies. 2015 , 27, 1-5	3
98	The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know. 2015 , 24, 705-32	3
97	Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. 2015 , 14, 117-28	12
96	Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. 2015 , 121, 25-33	298
95	A Review of the Clinical Implications of Breast Cancer Biology. 2016 , 8, 2416-24	24

94	Impact of Genetic Counseling and Testing on Altruistic Motivations to Test for BRCA1/2: a Longitudinal Study. 2016 , 25, 572-82		7
93	Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families. 2017 , 24, 238-244		12
92	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. 2017 , 23, 3628-3637		68
91	Breast Cancer Risk Assessment Models and High-Risk Screening. 2017 , 55, 457-474		17
90	Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. 2017 , 164, 263-284		86
89	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	102
88	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. 2017 , 24, 375-397		37
87	Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. 2017 , 130, e110-e126		100
86	Hereditary Breast and Ovarian Cancer. 2017 , 401-421		
85	The Preventive Intervention of Hereditary Breast Cancer. 2017 , 1026, 41-57		9
84	Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 994-1002	9.7	24
83	Breast Cancer Genetics. 2018 , 237-249.e5		2
82	Nonparametric Adjustment for Measurement Error in Time-to-Event Data: Application to Risk Prediction Models. 2018 , 113, 14-25		1
81	Breast Diseases. 2018 , 320-352.e6		0
80	Genes and Cancer. 2018 , 493-527.e6		
79	Changing Paradigms in the Management of Breast Cancer. 2018 ,		
78	Genetic Risk Prediction in Breast Cancer. 2018 , 217-232		0
77	Association between monoallelic mutations and congenital hypothyroidism: a statistical approach. 2018 , 178, 137-144		15

76	Screening for Ovarian Cancer. 2018,		
75	Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. <i>Genetic Epidemiology</i> , 2018 , 42, 528-538	2.6	1
74	Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. 2019 , 94, 1084-1098		22
73	A systematic review and quality assessment of individualised breast cancer risk prediction models. 2019 , 121, 76-85		48
72	Breast Disease. 2019,		
71	Mechanistic link between DNA damage sensing, repairing and signaling factors and immune signaling. 2019 , 115, 297-324		12
70	Risk Stratification for Screening Mammography: Benefits and Harms. 2019 , 212, 250-258		11
69	Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 489-497	9.7	22
68	Development of Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk. 2020 , 245, 153-162		1
67	Screening and Early Detection. 2020 , 375-398.e7		1
66	Breast MRI texture analysis for prediction of BRCA-associated genetic risk. 2020 , 20, 86		1
65	Assessing breast cancer risk within the general screening population: developing a breast cancer risk model to identify higher risk women at mammographic screening. 2020 , 30, 5417-5426		6
64	Key steps for effective breast cancer prevention. 2020 , 20, 417-436		120
63	Practical implementation of frailty models in Mendelian risk prediction. <i>Genetic Epidemiology</i> , 2020 , 44, 564-578	2.6	1
62	Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer. 2020 , 122, 1133-1140		11
61	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. 2020 , 9, 1744947		15
60	Breast cancer screening in women at high risk of hereditary breast cancer: an Australian experience. 2021 , 91, 685-690		0
59	A likelihood-based approach to assessing frequency of pathogenicity among variants of unknown significance in susceptibility genes. 2021 , 40, 593-606		

58	Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors. 2021 , 30, 342-360	3
57	Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. 2021 , 3, 144-155	7
56	Electronic Family History Screening Tool for Detection of Inherited Cancer Risk: A Prospective Pilot Study. 2021 , 36, 415-421	1
55	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. 2021 , 127, 3742-3750	2
54	Ethnic differences in cancer risk resulting from genetic variation. 1999 , 86, 1755-1762	8
53	Cancer Genetic Counseling. 2002 , 477-495	1
52	Genomic Cancer Risk Assessment. 2020 , 187-207	1
51	Update on breast cancer susceptibility genes. 1998 , 152, 49-59	10
50	Issues in bilateral prophylactic mastectomy. 2001 , 9, 6-10	1
49	Multiple Primary Cancers. 2006 , 1269-1280	6
48	Overestimation of hereditary breast cancer risk. 1998 , 228, 375-84	20
47	The family history component of cancer genetic risk counseling. 1999 , 22, 96-102	9
46	Why should primary care physicians know about breast cancer genetics?. 2001 , 175, 168-73	4
45	A model of perceived risk for colorectal cancer among Japanese Americans. 2004 , 19, 251-7	4
44	Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling. 2016 , 7, 86457-86468	5
43	Risk assessment and pharmacogenetics in molecular and genomic epidemiology. 2009 , 42, 371-6	5
42	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. 2021 , 125, 1712-1717	1
41	Prevention of Ovarian Serous Epithelial Carcinoma. 2003 , 515-543	

- 40 The Genetic Epidemiology of Hereditary Breast Cancer. **2007**, 1-17
- 39 Models of Absolute Risk. **2008**, 259-274
- 38 Genetic Risk Assessment for Hereditary Ovarian Cancer. **2008**, 219-235
- 37 The Genetics of Breast Cancer. **2009**, 39-54
- 36 High Risk Indicators: Microscopic Lesions, Personal and Family History, Assessment, and Management. **2010**, 39-60
- 35 Identification and Management of Women at High Familial Risk for Breast Cancer. **2010**, 135-145
- 34 Familial Cancer Risk Assessment Using BayesMendel. **2010**, 301-314
- 33 Hereditary Breast Cancer Syndromes. **2011**, 51-104
- 32 Malignant disease of the breast. **2011**, 707-749
- 31 Identifying Women at High Risk of Breast Cancer: Understanding the Risk Models. **2013**, 1-28
- 30 Clinical assessment of symptomatic patients. **2013**, 119-128
- 29 Cancer Prevention, Screening, and Early Detection. **2014**, 322-359.e12 1
- 28 Components of a Genetic Cancer Risk Clinic. **1999**, 1-26
- 27 Psychosocial Issues in BRCA1/2 Testing. **1999**, 247-266
- 26 Estimating Individualized Risk of Breast Cancer. **1999**, 39-53
- 25 Epidemiology, Risk Factors, and Prevention. **2016**, 57-87 1
- 24 Risk Assessment for Breast Cancer. **2017**, 1-14
- 23 Epidemiology, Risk Factors, and Prevention. **2019**, 39-61

22	Identifying High-Risk Female Patients. 2019 , 185-190		
21	Genetic Screening and Counseling for High-Risk Populations. 2006 , 341-357		
20	Implikationen der genetischen Beratung bei Hochrisiko-Familien f�bererblichen Brust- und Eierstockkrebs. 2005 , 33-58		1
19	Risikoberechnungen in Familien. 2007 , 279-326		
18	An Assessment of Family History Information Captured in an Electronic Health Record. 2015 , 2015, 2035-42		19
17	Investigation of CCR7 Marker Expression Using Immunohistochemical Method and Its Association with Clinicopathologic Properties in Patients with Breast Cancer. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2018 , 12, 103-110	0.5	3
16	Low Screening Rates for Diabetes Mellitus Among Family Members of Affected Relatives. 2018 , 2018, 1471-1477	0.7	1
15	Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.. <i>Frontiers in Oncology</i> , 2021 , 11, 740227	5.3	
14	Prediction of hereditary cancers using neural networks. <i>Annals of Applied Statistics</i> , 2022 , 16,	2.1	
13	Validation of Breast Cancer Risk Models by Race/Ethnicity, Family History and Molecular Subtypes.. <i>Cancers</i> , 2021 , 14,	6.6	1
12	Male Breast Cancer: From Molecular Genetics to Clinical Management.. <i>Cancers</i> , 2022 , 14,	6.6	0
11	Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer. 2022 , 87-112		
10	Statistical methods for Mendelian models with multiple genes and cancers.. <i>Genetic Epidemiology</i> , 2022 ,	2.6	1
9	Characteristics of breast cancer patients tested for germline BRCA1/2 mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University. <i>Cancer Reports</i> ,	1.5	
8	Promoter Hypermethylation in Benign Breast Epithelium in Relation to Predicted Breast Cancer Risk. 2005 , 11, 166-172		38
7	Risk prediction models for breast cancer: a systematic review. <i>BMJ Open</i> , 2022 , 12, e055398	3	0
6	Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn's disease. 2022 , 34, 983-992		0
5	Breast diseases. 2023 , 311-344.e7		0

- 4 Genes and cancer: Genetic counselling and clinical management. **2023**, 521-559.e6
- 3 Prediction ofBRCA1andBRCA2mutations by the BODICEA and BRCAPRO models and NCCN criteria in Libyan breast cancer women.
- 2 Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. **2023**, 198, 335-347
- 1 Variant-specific Mendelian Risk Prediction Model.